

CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

Fangkun Liu^{1,2†}, Jing Huang^{3,4}, Fengqiong He^{1,2}, Xiaodong Ma⁵, Fan Fan^{1,2}, Ming Meng^{1,2}, Yang Zhuo^{1,2}, and Liyang Zhang^{1,2*}

¹ Department of Neurosurgery, Xiangya Hospital, Central South University, Central South University; 87 Xiangya Road; Changsha, Hunan, 410008. China;

² Clinical Diagnosis and Therapy Center for Glioma of Xiangya Hospital, Central South University; 87 Xiangya Road; Changsha, Hunan, 410008. China;

³ Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China;

⁴ Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China;

⁵ Director and Training and Exchange Cooperation Center, Orient Science & Technology College, Hunan Agricultural University, Changsha, Hunan 410000, China.

†The first author;

*Corresponding Author:

Dr. Liyang Zhang MD, Ph. D

Department of Neurosurgery, Xiangya Hospital, Central South University

87 Xiangya Rd, Changsha, Hunan, 410008, China,

Email: zhangliyang@csu.edu.cn

Supplement Figure 3

A multivariate Survival Analysis of CD96 in Glioma patients

